TRex Bio (NASDAQ:TRXB) Releases Earnings Results, Misses Expectations By $9.37 EPS

TRex Bio (NASDAQ:TRXB) posted its quarterly earnings results on Friday. The company reported ($10.06) EPS for the quarter, missing analysts’ consensus estimates of ($0.69) by ($9.37), Zacks reports.

TRex Bio Trading Down 3.0%

Shares of NASDAQ:TRXB traded down $0.43 during midday trading on Friday, reaching $13.67. 62,668 shares of the company traded hands, compared to its average volume of 106,799. TRex Bio has a 12 month low of $12.50 and a 12 month high of $16.56.

Insider Buying and Selling

In related news, major shareholder Alexandria Venture Investments bought 178,571 shares of the business’s stock in a transaction on Tuesday, October 13th. The stock was acquired at an average price of $14.00 per share, for a total transaction of $2,499,994.00. Following the purchase, the insider directly owned 1,346,501 shares in the company, valued at $18,851,014. This trade represents a 15.29% increase in their ownership of the stock. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website.

Analyst Ratings Changes

TRXB has been the subject of a number of recent research reports. Evercore assumed coverage on TRex Bio in a research report on Tuesday, November 3rd. They issued a “strong-buy” rating for the company. Wedbush started coverage on TRex Bio in a research note on Monday, November 2nd. They issued an “outperform” rating and a $30.00 target price on the stock. Zacks Research assumed coverage on TRex Bio in a research report on Tuesday, November 3rd. They set a “hold” rating on the stock. Cantor Fitzgerald began coverage on TRex Bio in a research note on Tuesday, November 3rd. They set an “overweight” rating for the company. Finally, Stifel Nicolaus started coverage on TRex Bio in a report on Tuesday, November 3rd. They issued a “buy” rating and a $39.00 price objective for the company. One analyst has rated the stock with a Strong Buy rating, four have assigned a Buy rating and one has assigned a Hold rating to the stock. According to data from MarketBeat.com, the company has an average rating of “Buy” and an average target price of $29.67.

TRex Bio Company Profile

We are a clinical-stage biopharmaceutical company focused on tissue Treg biology for the discovery and development of immunoregulatory medicines designed to restore immune balance and promote tissue repair to address unmet needs of patients with autoimmune and inflammatory diseases. TRexBio was built on a pivotal scientific insight: that regulatory T cells (“Tregs”) in human tissue are not merely passive suppressors of inflammation, but active orchestrators of tissue immune homeostasis and repair.